Evidence map›Paper›PMID 37060054›Full record

ArticleBMC public health2023

Burden of smoking on disease-specific mortality, DALYs, costs: the case of a high-income European country.

Renato Farcher, Maria Eleni Syleouni, Linda Vinci, Renato Mattli

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Analysis of COPD: Distinguishing Characteristics and Management of Smoking vs Never Smoking Patients.International journal of chronic obstructive pulmonary disease · 2024
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Renato Farcher *Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland.
Maria Eleni Syleouni *Winterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland.
Linda VinciWinterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland. vinc@zhaw.ch.
Renato MattliWinterthur Institute of Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, Winterthur, 8401, Switzerland.
ZHAW Zurich University of Applied Sciences · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoking is a major risk factor for chronic diseases causing early death and disability. Smoking prevalence over the past 25years has remained high in Switzerland. Evidence about the burden of disease and cost of illness attributable to smoking can support tobacco control. The aim of the present paper is to quantify from a societal perspective the mortality, disability-adjusted life years (DALYs), medical costs and productivity losses attributable to smoking in Switzerland in 2017.

methodsSmoking attributable fractions (SAFs) were calculated based on the prevalence of current and former active smoking in the latest Swiss Health Survey from 2017 and relative risks from the literature. The SAFs were then multiplied with the number of deaths, DALYs, medical costs and productivity losses in the total population.

resultsIn the Swiss population in 2017 smoking accounted for 14.4% of all deaths, for 29.2% of the deaths due to smoking-related diseases, 36.0% of the DALYs, 27.8% of the medical costs and 27.9% of productivity losses. Total costs amounted to CHF 5.0 billion which equals CHF 604 per capita per year. The highest disease burden in terms of mortality and DALYs attributable to smoking was observed for lung cancer and chronic obstructive pulmonary disease (COPD), whereas the highest cost of illness in terms of medical costs was observed for coronary heart diseases and lung cancer and in terms of productivity losses for COPD and coronary heart diseases. Sex and age group differences were found.

conclusionsWe provide an estimate of the burden of smoking on disease-specific mortality, DALYs, medical costs and productivity losses in Switzerland that could be prevented through evidence-based tobacco prevention and control policies as well as regular monitoring of tobacco consumption.

Indexed as

Disability-Adjusted Life YearsPulmonary Disease, Chronic ObstructiveCost of IllnessHumansQuality-Adjusted Life YearsRisk FactorsSmokingBurden of diseaseChronic diseaseCost of illnessSmoking

Identifiers

PMID37060054
PMCPMC10103371
OpenAlexW4365513875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.